CN115400170A - 一种抗新冠病毒的中、西药物组合物 - Google Patents
一种抗新冠病毒的中、西药物组合物 Download PDFInfo
- Publication number
- CN115400170A CN115400170A CN202110186377.0A CN202110186377A CN115400170A CN 115400170 A CN115400170 A CN 115400170A CN 202110186377 A CN202110186377 A CN 202110186377A CN 115400170 A CN115400170 A CN 115400170A
- Authority
- CN
- China
- Prior art keywords
- chinese
- western medicine
- preparation
- new
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 34
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 10
- 229940079593 drug Drugs 0.000 claims abstract description 10
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- 229960000329 ribavirin Drugs 0.000 claims abstract description 6
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims abstract description 6
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 5
- 235000018958 Gardenia augusta Nutrition 0.000 claims abstract description 5
- 244000299790 Rheum rhabarbarum Species 0.000 claims abstract description 4
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims abstract description 4
- 241000207929 Scutellaria Species 0.000 claims abstract description 4
- 235000012907 honey Nutrition 0.000 claims abstract description 4
- 241000758993 Equisetidae Species 0.000 claims abstract description 3
- 241000700605 Viruses Species 0.000 description 21
- 230000000694 effects Effects 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000000284 extract Substances 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 241000712461 unidentified influenza virus Species 0.000 description 5
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 4
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 4
- 102100031673 Corneodesmosin Human genes 0.000 description 4
- 239000010282 Emodin Substances 0.000 description 4
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 4
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 4
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 4
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 4
- 241000315672 SARS coronavirus Species 0.000 description 4
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 4
- 229940015301 baicalein Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 4
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 3
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 229940126673 western medicines Drugs 0.000 description 3
- 101710139375 Corneodesmosin Proteins 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 235000013902 inosinic acid Nutrition 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 101150013191 E gene Proteins 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 1
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Natural products C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 101000595751 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 description 1
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- 101000595548 Homo sapiens TIR domain-containing adapter molecule 1 Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- 101150062031 L gene Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 101710145006 Lysis protein Proteins 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001292005 Nidovirales Species 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 108091005532 SARS-CoV-2 main proteases Proteins 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100036073 TIR domain-containing adapter molecule 1 Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 102000008395 cell adhesion mediator activity proteins Human genes 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960004525 lopinavir Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Insects & Arthropods (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Husbandry (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种新的中、西药物组合物、制备方法、制剂及应用，作为抗病毒药物或治疗新冠状病毒的药物，这种新的中、西药物组合物。本发明公开了一种由黄芩提取物黄芩提取物30％‑45％，栀子提取物20％‑40％，大黄提取物5％‑10％，利巴韦林1％‑2％，蜂蜜10％～20％。组成的新的中西药物组合物、制备方法、制剂及应用，可以是中药的复方，也可以是中西药复方，也可以是在本基础方上产生的系列新药，作为抗病毒药物或治疗新冠病毒的组合物。
Description
一种新的中、西药物组合物、制备方法、制剂及应用
技术领域
本发明涉及一种新的中、西药物组合物、制备方法、制剂及应用，作为抗病毒药物或治疗新冠状病毒的药物，这种新的中、西药物组合物。
背景技术
在新冠肺炎(COVID-19)疫情爆发之后没多久，发现：新型冠状病毒和 SARS病毒一样，也是通过利用S蛋白结合人体细胞表面的ACE2蛋白进入细胞的。冠状病毒属于尼多病毒目冠状病毒科，冠状病毒的E蛋白和M蛋白主要参与病毒的装配过程，N蛋白包裹基因组形成核蛋白复合体。有包膜的单股、正链RNA病毒，分为α，β和γ三个属。针对新冠病毒，目前依然缺少蛋白类、抗体类的诊断和治疗手段。对于新冠病毒的诊断研发，新冠病毒的抗体药物治疗手段，将以S蛋白和ACE2的中和抗体为研发目标，目前没有十分的特效药物。
本发明从病毒基因的表达、突变、抑制、转录，调控、变异，总结治疗病毒的方法，特别对新冠状病毒有优势的治疗作用。发明者采用各个因素结合，运用中西结合、优势互补，全面、创新治疗病毒，效果明显优于中药和西药的单独使用。有可能成为治疗新冠状病毒有优势的中西结合组合物，成为治疗新冠状病毒时间短、价格低廉、见效快的特效药。
发明内容：
本发明公开了一种由黄芩提取物黄芩提取物30％-45％，栀子提取物20％-40％，大黄提取物5％-10％，利巴韦林1％-2％，蜂蜜10％～20％。组成的新的中西药物组合物、制备方法、制剂及应用，可以是中药的复方，也可以是中西药复方，也可以是在本基础方上产生的系列新药，作为抗病毒药物或治疗新冠病毒的组合物。
黄芩素具有广谱抗病毒、抗菌、抗炎作用，它的抗病毒作用包括抗RNA 病毒、HIV病毒、呼吸道合胞病毒、登革热病毒、流感病毒以及抗DNA病毒。黄芩素与新冠病毒3CL水解酶的结合能与洛匹那韦和瑞德西韦相同，且黄芩素与ACE2的结合能力强。黄芩素可能通过作用于PIK3CG和AKT1靶点调节T 细胞受体信号通路治疗新冠病毒，它可呈剂量依赖性抑制H1N1病毒mRNA中后期合成。黄芩的乙醇提取物在体外抑制SARS-CoV-2 3CLpro活性和SARS-CoV-2在Vero细胞中的复制，作用于PTGS2、HSP90AA1、ESR1 等靶点调节，可以多途径多靶点作用于新冠病毒。
栀子提取物是治疗温毒疫病的要药，在体外对流感病毒等6种病毒引起的细胞病变有明显抑制作用[。
栀子水提取物延长出血时间、凝血时间，抑制血栓形成及抑制ADP诱导血小板聚集。栀子苷可能通过调节TLR3/TRIF通路介导的p-NF-κ B65活性增强机体的抗病毒能力，抑制NF-κ B/Iκ B通路和细胞黏附分子产生等药理活性，具有抗哮喘、抗炎镇痛、保肝利胆、抗病毒、抗肿瘤等作用。栀子提取物 T9可能通过上调单纯疱疹病毒感染小鼠脑内IFN-γmRNA相对表达量，来抑制单纯疱疹病毒在小鼠脑内的复制。
大黄素作为蓼科植物大黄及虎杖的主要活性成分，具有广谱的抗病毒活性，对包括SARS冠状病毒(SARS-CoV)、流感病毒、HIV病毒、HBV病毒等的感染和复制具有抑制作用。本品主要通过抑制病毒的吸附和穿入过程而阻止病毒复制，在基因转录水平抑制IE2 mRNA表达，阻碍E基因L基因的转录表达，致使病毒复制周期无法按线性完成。大黄素对SARS-CoV有抑制作用，可以显著阻断S-蛋白与血管紧张素转换酶蛋白的相互作用，并能抑制S-蛋白逆转录病毒的感染。
大黄素具有良好的抗人巨细胞病毒HCMV的临床应用前景，同时大黄素在细胞水平上可抑制HCMV AD169株的即刻早期、早期、晚期基因的转录水平，表明大黄素对HCMV病毒基因的早期干预是其抗病毒的主要环节。
利巴韦林抑制呼吸道合胞病毒、流感病毒、甲肝病毒、腺病毒等多种病毒生长的作用。本品并不改变病毒吸附、侵人和脱壳，也不诱导干扰素的产生。药物进入被病毒感染的细胞后迅速磷酸化，其产物作为病毒合成酶的竞争性抑制药，抑制肌苷单磷酸脱氢酶、流感病毒RNA多聚酶和mRNA鸟苷转移酶，从而引起细胞内三磷酸鸟苷的减少，损害病毒RNA和蛋白合成，抑制肌苷单磷酸脱氢酶(GTP合成所必须)的活性，可阻止许多RNA和DNA病毒的复制，干扰了病毒的复制、合成过程，最终导致RNA基因的致死性突变，使病毒的复制与传播受抑。
本发明从理论上，分析病毒基因的背景影响，从病毒基因的表达、突变、抑制、转录，调控、变异，总结治疗病毒的方法，特别对新冠状病毒有优势的治疗作用。发明者采用各个因素结合，运用中西结合、优势互补，全面、创新治疗病毒，效果明显优于中药和西药的单独使用。
注意事项：有不稳定心脏病史的患者，有严重贫血者不宜用，对本品过敏者禁用；孕妇及其男性伴侣禁用；血红蛋白病患者禁用；自身免疫性肝炎患者禁忌利巴韦林与干扰素α2b或peg干扰素α合用。
具体实施方式：
治疗病毒或新冠病毒中药、西药，由下述百分比的原料组成：
黄芩提取物30％-45％，栀子提取物20％-40％，大黄提取物5％-10％，
利巴韦林1％-2％，蜂蜜10％～20％
将上述中药、西药放入粉碎机一起粉碎，干燥、高压灭毒，达成目数，即为成药。
本处方按百分比组成成药150克，每次15克左右，分10次，每日三次，早、中、晚用温开水服用。
Claims (1)
1.本发明公开了一种由黄芩提取物黄芩提取物30％-45％，栀子提取物20％-40％，大黄提取物5％-10％，利巴韦林1％-2％，蜂蜜10％～20％。组成的新的中西药物组合物、制备方法、制剂及应用，可以是中药的复方，也可以是中西药复方，也可以是在本基础方上产生的系列新药，作为抗病毒药物或治疗新冠病毒的组合物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110186377.0A CN115400170A (zh) | 2021-02-10 | 2021-02-10 | 一种抗新冠病毒的中、西药物组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110186377.0A CN115400170A (zh) | 2021-02-10 | 2021-02-10 | 一种抗新冠病毒的中、西药物组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115400170A true CN115400170A (zh) | 2022-11-29 |
Family
ID=84154795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110186377.0A Pending CN115400170A (zh) | 2021-02-10 | 2021-02-10 | 一种抗新冠病毒的中、西药物组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115400170A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102228547A (zh) * | 2011-06-29 | 2011-11-02 | 吉林一正药业集团有限公司 | 一种中药组合物在制备治疗胰腺炎和/或胆囊炎药物中的应用 |
| CN103110694A (zh) * | 2011-11-17 | 2013-05-22 | 广东紫金正天药业有限公司 | 一种广泛治疗病毒性疾病的组合物及其用途 |
-
2021
- 2021-02-10 CN CN202110186377.0A patent/CN115400170A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102228547A (zh) * | 2011-06-29 | 2011-11-02 | 吉林一正药业集团有限公司 | 一种中药组合物在制备治疗胰腺炎和/或胆囊炎药物中的应用 |
| CN103110694A (zh) * | 2011-11-17 | 2013-05-22 | 广东紫金正天药业有限公司 | 一种广泛治疗病毒性疾病的组合物及其用途 |
Non-Patent Citations (2)
| Title |
|---|
| 赵军宁;戴瑛;华桦;曾瑾;杨思进;谢春光;王超;鄢良春;李莉;张翼冠;尹竹君;张磊;: "治疗新冠病毒肺炎(COVID-19)中药"药理谱-云"特点与有效性评价要素", 中药药理与临床, vol. 36, no. 01, pages 2 - 11 * |
| 陈冉;王婷婷;李开铃;尚锐峰;宋杰;张景?;: "免疫调节抗病毒中药的特性与应用", 中草药, no. 06, pages 1412 - 1426 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shiraki et al. | Favipiravir, an anti-influenza drug against life-threatening RNA virus infections | |
| Glatthaar-Saalmüller et al. | Antiviral activity in vitro of two preparations of the herbal medicinal product Sinupret® against viruses causing respiratory infections | |
| Huang | Human cytomegalovirus. IV. Specific inhibition of virus-induced DNA polymerase activity and viral DNA replication by phosphonoacetic acid | |
| CA2163456C (en) | New procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis | |
| de Magalhaes et al. | A mitogenic signal triggered at an early stage of vaccinia virus infection: implication of MEK/ERK and protein kinase A in virus multiplication | |
| Smee et al. | Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir | |
| Julander et al. | Treatment of Venezuelan equine encephalitis virus infection with (−)-carbodine | |
| Al Awadh | Nucleotide and nucleoside-based drugs: past, present, and future | |
| Fu et al. | Scutellaria baicalensis inhibits coxsackievirus B3-induced myocarditis via AKT and p38 pathways | |
| JPH0285215A (ja) | Ｂ型肝炎の抗ウイルス剤による治療方法 | |
| CN115400170A (zh) | 一种抗新冠病毒的中、西药物组合物 | |
| Dhapola et al. | Update on monkeypox virus infection: Focusing current treatment and prevention approaches | |
| Camero et al. | Enhancement of the antiviral activity against caprine herpesvirus type 1 of Acyclovir in association with Mizoribine | |
| CN112156099A (zh) | 一种应用于HIV、HBV、nCoV抗病毒治疗的复合制剂 | |
| CA2465062C (en) | Preventive and/or therapeutic agent for viral infection | |
| Hirsch et al. | Antiviral therapy | |
| CN102068452B (zh) | 一种具有抗病毒作用的药物组合物 | |
| EP3677258A1 (en) | Uses of cannabidiol in preparation of drugs for resisting against influenza | |
| US20230210866A1 (en) | Composition comprising diltiazem for treating a viral infection caused by sars-cov-2 viruses | |
| De Clercq | Perspectives for antivirals to limit SARS-CoV-2 infection (COVID-19) | |
| Gröschel et al. | ddC-and 3TC-bis (SATE) monophosphate prodrugs overcome cellular resistance mechanisms to HIV-1 associated with cytidine kinase deficiency | |
| RU2597150C2 (ru) | Противовирусное соединение множественного действия, его состав и способ лечения вирусных заболеваний | |
| CN104771384A (zh) | 紫草素的医药用途 | |
| Mahmood et al. | Plant-Based Drugs and Vaccines for COVID-19. Vaccines. 2021; 9: 15 | |
| CN102657673A (zh) | 注射用穿琥宁冻干粉组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |